Suppr超能文献

用外泌体递送的miR-126强制喂食恶性间皮瘤干细胞样细胞可诱导肿瘤细胞死亡。

Force-feeding malignant mesothelioma stem-cell like with exosome-delivered miR-126 induces tumour cell killing.

作者信息

Monaco Federica, De Conti Laura, Vodret Simone, Zanotta Nunzia, Comar Manola, Manzotti Sandra, Rubini Corrado, Graciotti Laura, Fulgenzi Gianluca, Bovenzi Massimo, Baralle Marco, Tomasetti Marco, Santarelli Lory

机构信息

Department of Clinical and Molecular Sciences, Polytechnic University of Marche, Ancona, Italy; Department of Excellence SBSP-Biomedical Sciences and Public Health, Polytechnic University of Marche, Ancona, Italy.

RNA biology Group, International Centre for Genetic Engineering and Biotechnology (ICGEB), Trieste, Italy.

出版信息

Transl Oncol. 2022 Jun;20:101400. doi: 10.1016/j.tranon.2022.101400. Epub 2022 Mar 23.

Abstract

Malignant pleural mesothelioma (MPM) is an aggressive tumour resistant to treatments. It has been postulated that cancer stem cells (CSCs) persist in tumours causing relapse after multimodality treatment. In the present study, a novel miRNA-based therapy approach is proposed. MPM-derived spheroids have been treated with exosome-delivered miR-126 (exo-miR) and evaluated for their anticancer effect. The exo-miR treatment increased MPM stem-cell like stemness and inhibited cell proliferation. However, at a prolonged time, the up taken miR-126 was released by the cells themselves through exosomes; the inhibition of exosome release by an exosome release inhibitor GW4869 induced miR-126 intracellular accumulation leading to massive cell death and in vivo tumour growth arrest. Autophagy is involved in these processes; miR-126 accumulation induced a protective autophagy and the inhibition of this process by GW4869 generates a metabolic crisis that promotes necroptosis, which was associated with PARP-1 over-expression and cyt-c and AIF release. Here, for the first time, we proposed a therapy against CSCs, a heterogeneous cell population involved in cancer development and relapse.

摘要

恶性胸膜间皮瘤(MPM)是一种对治疗具有抗性的侵袭性肿瘤。据推测,癌症干细胞(CSCs)在肿瘤中持续存在,导致多模态治疗后复发。在本研究中,提出了一种基于miRNA的新型治疗方法。用外泌体递送的miR-126(exo-miR)处理MPM来源的球体,并评估其抗癌效果。exo-miR处理增加了MPM干细胞样干性并抑制细胞增殖。然而,在较长时间后,摄取的miR-126会被细胞自身通过外泌体释放;外泌体释放抑制剂GW4869对外泌体释放的抑制导致miR-126在细胞内积累,从而导致大量细胞死亡和体内肿瘤生长停滞。自噬参与了这些过程;miR-126积累诱导了保护性自噬,而GW4869对这一过程的抑制产生了促进坏死性凋亡的代谢危机,这与PARP-1过表达以及细胞色素c和凋亡诱导因子的释放有关。在此,我们首次提出了一种针对CSCs的治疗方法,CSCs是参与癌症发展和复发的异质性细胞群体。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3a81/8956928/fba09e6a2884/ga1.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验